ISRCTN42293056已完成1 期
A phase 1, double-blind study investigating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of intravenous (IV) and intramuscular (IM) dosing of SPL028 (deuterated DMT fumarate [a serotonergic psychedelic]) in healthy participants (Part A); followed by an open-label study investigating the safety, tolerability, pharmacokinetics, pharmacodynamics and exploratory efficacy of SPL028 in participants with major depressive disorder (Part B)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Cybin UK Ltd
- 入组人数
- 38
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Participant has a body mass index (BMI) of 18 to 33.9 kg/m², inclusive.
- •2. Participant has not been administered any Monoamine Oxidase (MAO) inhibitor class antidepressants for at least 3 months prior to Screening.
- •3. Registered with a GP in the UK.
- •4. Sufficient intelligence to understand the nature of the trial and any hazards of participation in it. Ability to communicate satisfactorily with the Investigator and therapist team to participate in, and comply with the requirements of, the entire trial.
- •5. Healthy as determined by a responsible physician, based on no clinically significant findings from medical evaluation including medical history, a physical examination, concomitant medication, vital signs, 12-lead ECG and clinical laboratory evaluations (including haematology, coagulation, biochemistry and urinalysis) at the Screening visit and admission.
- •6. Agree to follow the contraception requirements of the trial.
- •7. Willing to be contacted by email and telephone and video call.
- •8. Proficient in reading and writing English sufficient to complete questionnaires.
- •9. Willing to give written consent to have data entered into The Over-volunteering Prevention System.
- •10. Provision of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form, after having the opportunity to discuss the trial with the Investigator or their delegate.
- •Part A – Cohorts 1 and 2 Only
- •1. Healthy participants aged 25 to 65 years, inclusive.
- •2. Healthy psychedelic-experienced participants (psychedelic-experienced is defined as having at least two previous experiences, with breakthrough [see Section 3.3.1 for definition], of serotonergic psychedelic drugs, including but not limited to: DMT, ayahausca, LSD, LSA [morning glory seeds], 2,5-Dimethoxy-4-iodoamphetamine [DOI], dimethoxybromoamphetamine [DOB], 2,5-Dimethoxy-4 chloroamphetamine [DOC], 2-(4-bromo-2,5-dimethoxyphenyl)ethanamine [2CB], 1-(2,5-Dimethoxy-4-ethylphenyl)-2-aminoethane [2CE], mescaline, peyote, san pedro, ibogaine and psilocybin [including mushroom species containing psilocybin]).
- •3. No psychedelic drug use 6 weeks prior to dosing (excluding the study drug) until the end of the study.
- •Part A – Cohorts 3, 4 and 5 Only
- •1. Healthy participants aged 25 to 65 years, inclusive.
- •2. Healthy participants with little to no psychedelic experience (defined as a maximum of two previous experiences that weren’t breakthrough, including but not limited to: DMT, ayahausca, LSD, LSA, DOI, DOB, DOC, 2CB, 2CE, mescaline, peyote, san pedro, ibogaine and psilocybin [including mushroom species containing psilocybin]).
- •3. No psychedelic drug use 6 months prior to dosing (excluding the study drug) until the end of the study.
排除标准
- •Psychiatric Exclusion Criteria
- •Participants with any of the following will be excluded from study participation:
- •1. Participant meets the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for substance abuse disorder, as assessed by the Mini International Neuropsychiatric Interview (MINI) Version 7.0.2 at Screening, or a positive urine drugs of abuse result at Screening or Day -1 (excluding cannabis which is permitted to be taken up to 24 hours before each trial visit, but which may be detected in urine). Repeat tests may be considered by the Investigator with justification.
- •2. Current or clinically relevant history of a psychotic disorder, including schizophrenia, psychosis, bipolar disorder, delusional disorder, paranoid personality disorder, schizoaffective disorder, borderline personality disorder, emotionally unstable personality disorder or panic disorder, as assessed by a structured clinical interview (including the MINI Version 7.0.2).
- •3. In first-degree relatives, a clinically relevant history of a psychotic disorder, including schizophrenia, psychosis, bipolar disorder, delusional disorder, paranoid personality disorder or schizoaffective disorder. Significant history of mania (as determined by the Investigator and medical records, in agreement with the Sponsor’s Medical Monitor).
- •4. Significant history of mania (as determined by the Investigator and medical records, in
- •agreement with the Sponsor’s Medical Monitor).
- •5. Psychiatric condition judged to be incompatible with establishment of rapport with the therapy team and/or safe exposure to DMT, based on the Investigator’s clinical evaluation (e.g., borderline personality disorder).
- •6. Significant suicide risk, as defined by:
- •6.1. Suicidal ideation as endorsed on the BSS within 1 year prior to Screening or on Day -1, or
- •6.2. Suicidal behaviours within 1 year prior to Screening, or
- •6.3. History of serious suicide attempts in lifetime (i.e., those that require hospitalisation), or
- •6.4. Clinical assessment of significant suicide risk during Participant interview
- •General Medical Exclusion Criteria
- •Participants with any of the following will be excluded from study participation:
- •1. Clinically relevant history of abnormal physical or mental health interfering with the study as determined by medical history and physical examinations obtained during Screening, as judged by the Investigator (including [but not limited to]: neurological, psychiatric, endocrine, thyroid, cardiovascular, respiratory, GI, hepatic, haematological, musculoskeletal, immunological, renal, connective tissue diseases or disorders or any other medically relevant condition as judged by the Investigator).
- •2. Clinically relevant abnormal laboratory results (including hepatic and renal panels, complete blood count, chemistry panel and urinalysis), 12-lead ECG and vital signs, or physical findings at Screening and/or Day -1 as judged by the Investigator, that in the Investigator’s opinion may constitute a risk for an individual who is exposed to DMT.
- •In case of uncertain or questionable results, tests performed during Screening may be repeated to confirm eligibility or judged to be clinically irrelevant for healthy participants.
- •3. Any acute condition or infection, or history of chronic illness or condition, that could interfere with, or for which the treatment might interfere with, the conduct of the study as outlined in this Protocol, or that would, in the opinion of the Investi
研究者
相似试验
进行中（未招募）
1 期
A randomised, double-blind study evaluating the safety, tolerability and clinical outcome of Neoven compared to Vaminolact in premature ELBW infantsThe product is aimed to be used where parenteral nutrition is required. The intended indication is: Supply of essential and non-essential amino acids as part of Parenteral Nutrition for premature extreme low birth weight (ELBW) infants, when oral or enteral nutrition is impossible, insufficient or contraindicated.MedDRA version: 12.1 Level: LLT Classification code 10051284 Term: Parenteral nutritionEUCTR2009-012603-26-BEFresenius Kabi Deutschland GmbH17
进行中（未招募）
不适用
A randomised, double-blind study evaluating the safety, tolerability, and amino acid plasma levels of Neoven compared to Vaminolact in infants after surgical interventions.The product is aimed to be used where parenteral nutrition is required.The indended indication is: Supply of essential and non-essential amino acids as part of parenteral nutrition for preterm and fullterm neonates, infants and children, when oral or enteral nutrition is impossible, insufficient or contraindicated.MedDRA version: 9.1Level: LLTClassification code 10051284Term: Parenteral nutritionEUCTR2008-000429-20-NLFresenius Kabi Deutschland GmbH18
进行中（未招募）
1 期
A randomised, double-blind study evaluating the safety, tolerability and clinical outcome of Neoven compared to Vaminolact in premature ELBW infantsThe product is aimed to be used where parenteral nutrition is required. The intended indication is: Supply of essential and non-essential amino acids as part of Parenteral Nutrition for premature extreme low birth weight (ELBW) infants, when oral or enteral nutrition is impossible, insufficient or contraindicated.MedDRA version: 12.1 Level: LLT Classification code 10051284 Term: Parenteral nutritionEUCTR2009-012603-26-FRFresenius Kabi Deutschland GmbH17
进行中（未招募）
不适用
A randomised, double-blind study evaluating the safety, tolerability, and amino acid plasma levels of Neoven compared to Vaminolact in infants after surgical interventions.The product is aimed to be used where parenteral nutrition is required.The indended indication is: Supply of essential and non-essential amino acids as part of parenteral nutrition for preterm and fullterm neonates, infants and children, when oral or enteral nutrition is impossible, insufficient or contraindicated.MedDRA version: 9.1Level: LLTClassification code 10051284Term: Parenteral nutritionEUCTR2008-000429-20-BEFresenius Kabi Deutschland GmbH18
已完成
3 期
A randomised, double-blind study evaluating the safety, tolerability, protein accretion, amino acid plasma levels and long-term outcome of Neoven compared to Vaminolact in premature very low birth weigth (VLBW) infants.need for parenteral foodneed of food through infusion when feeding through the mouth is not posible10037008NL-OMON34823Fresenius Kabi Deutschland GmbH110